Journal
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
Volume 90, Issue 2, Pages 167-174Publisher
CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
DOI: 10.1139/Y11-121
Keywords
advanced glycation end-products; grape seed extract; procyanidins; HPLC-DAD-ELSD; Vitis vinifera; antiglycation
Categories
Funding
- Canadian Institutes of Health Research [CTP-79855]
- Natural Sciences and Engineering Research Council of Canada
Ask authors/readers for more resources
Eight commercial grape seed products (GSPs) were assessed for their inhibition of the formation of advanced glycation end-products in vitro. All 8 commercial GSPs included in this study were potent inhibitors of advanced glycation end-product formation with IC50 values ranging from 2.93 to 20.0 mu g/mL. Total procyanidin content ranged from 60% to 73%. HPLC-DAD-ELSD results indicate that (+)-catechin, (-)-epicatechin, procyanidin B1, and procyanidin B2 were predominant and ubiquitously present in all the products under study, while gallic acid and procyanidin B4 were present in relatively minor amounts. The IC50 values correlated with total phenolic content, and multiple regression analysis indicated that IC50 is a linear function of the concentration of gallic acid and procyanidins B1, B2, and B4. Based on this study, GSPs have the potential to complement conventional diabetes medication toward disease management and prevention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available